Autosomal dominant centronuclear myopathy is a rare congenital myopathy characterized by delayed motor milestones and muscular weakness. In 11 families affected by centronuclear myopathy, we identified recurrent and de novo missense mutations in the gene dynamin 2 (DNM2, 19p13.2), which encodes a protein involved in endocytosis and membrane trafficking, actin assembly and centrosome cohesion. The transfected mutants showed reduced labeling in the centrosome, suggesting that DNM2 mutations might cause centronuclear myopathy by interfering with centrosome function.
Autosomal dominant centronuclear myopathy (CNM) is a congenital myopathy characterized by slowly progressive muscular weakness and wasting 1 . The disorder involves mainly limb girdle, trunk and neck muscles but may also affect the distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Some affected individuals become wheelchair-bound in their fifties. Ptosis and limitation of eye movements occur frequently. The most prominent histopathological features include high frequency of centrally located nuclei in a large number of the extrafusal muscle fibers, radial arrangement of sarcoplasmic strands around the central nuclei and predominance and hypotrophy of type 1 fibers 2,3 . The severe X-linked form of CNM, X-linked myotubular myopathy, is caused by mutations in the gene MTM1, which encodes myotubularin, a highly conserved phosphoinositide phosphatase probably involved in membrane trafficking 4 .
We carried out genome-wide linkage mapping analysis in two families with autosomal dominant CNM (families 1 and 2) with eight and six affected members, respectively (Supplementary Methods online). Only three markers, D19S884, D19S865 and D19S226, gave positive lod scores in these two families. We confirmed that this locus was linked to CNM by genotyping other affected family members and a third multigenerational family (family 3). We genotyped additional microsatellite markers and identified several recombination events that narrowed the CNM locus on chromosome 19p13.2 to a 11.03-Mb interval between D19S1034 and D19S899 (Supplementary Table 1 and Supplementary Fig. 1 online) .
To identify proteins potentially responsible for the morphological abnormalities observed in CNM, we evaluated candidate proteins using three criteria: (i) expression in skeletal muscle, (ii) involvement in membrane trafficking (myotubularin-like hypothesis) and (iii) direct or indirect involvement in cytoskeleton. This focused our attention on ubiquitous protein dynamin 2 (DNM2), encoded by DNM2 (ref. 5) . Dynamins are large GTPases involved in membrane trafficking that act as mechanochemical scaffolding molecules that can hydrolyze GTP to deform biological membranes 6 . Among the dynamin family, the 100-kDa GTPase DNM2 has roles in endocytosis at the plasma membrane 6 , membrane trafficking from the trans-Golgi network 7 , formation of actin stress-fibers 8 , actin-membrane interface assembly 9 and centrosome cohesion 10 .
We sequenced exons and intron-exon boundaries of DNM2 in the probands of families 1-3 and identified heterozygous missense mutations ( Table 1 and Supplementary Fig. 2 online). Two were located in exon 8, 1106G-A resulting in the amino acid substitutions R369Q in family 2 and 1105C-T resulting in the amino acid substitution R369W in family 3. In family 1, a mutation in exon 11 (1395C-T) resulted in the amino acid substitution R465W. We also identified missense mutations in eight additional families with either dominant inheritance or sporadic cases of CNM. The R465W mutation was present in five additional families and the R369Q mutation in two others ( Table 1) . Genotyping of SNPs surrounding the R369Q and R465W mutations uncovered several genetic backgrounds among individuals sharing the same mutation (data not shown). We identified a new missense mutation, 1102G-A, resulting in the amino acid substitution E368K, in the proband of family 4, which was not found in the parents. We confirmed paternity of the proband and therefore concluded that the mutation occurred de novo. The R369W mutation in family 3 was also probably a de novo event ( Supplementary Fig. 1 ).
All the mutations cosegregated with the disease in the 11 families and were not found in 150 healthy control subjects of European descent screened by single strand conformation polymorphism analysis (for mutations R465W and E368K) or restriction enzyme digestion using AciI (for mutations R369W and R369Q, because single strand conformation polymorphism profiles were not informative for these mutations; Supplementary Fig. 2 ). Taken together, our results suggest that DNM2 mutations cause CNM. The severity of disease in affected individuals carrying one of the two most frequent mutations did not differ greatly, but disease onset occurred earlier in some individuals carrying the R465W mutation compared with those carrying the R369Q mutation. This observation needs to be confirmed in a larger sample of individuals.
The three mammalian dynamins share the same protein structure ( Supplementary Fig. 3 online) , with an N-terminal tripartite GTPase domain, a middle domain, a pleckstrin homology domain, a GTPase effector domain and a C-terminal proline rich domain. DNM2 mutations restricted to the pleckstrin homology domain, which mediates interaction with phosphoinositides, were recently identified in the dominant intermediate form of Charcot-MarieTooth disease type B 11 . In CNM, the four mutations, affecting three highly conserved residues ( Supplementary Fig. 3 ), were all restricted to the middle domain. The middle domain is involved in self-assembly of the molecule 12 , and the GTPase activity induces a conformational change of this domain associated with a constriction of lipidic structures 13 . Moreover, the middle domain is essential for the centrosomal localization of DNM2 (ref. 10) .
To explore the capability of DNM2 mutants to localize to the centrosome, we prepared green fluorescent protein (GFP) chimeras using wild-type, R369W and R465W DNM2 constructs. Wild-type DNM2-GFP was detected in the centrosome in transfected human fibroblasts. In contrast, the fluorescence associated with the centrosome was markedly reduced in the fibroblasts transfected with mutant DNM2-GFP constructs and was almost absent in roughly one-half of the fibroblasts transfected with R465W DNM2 (Fig. 1a) . In addition, we observed similar levels of DNM2 in fibroblasts from controls and from individuals with CNM carrying the R465W mutations, as measured by both cell immunolabeling and western blotting (Fig. 1b,c) , suggesting that the mutant protein was relatively stable. On the basis of these results, we hypothesize that mutations might hinder either the transport of DNM2 to the centrosome or its interaction with some centrosomal components, such as g-tubulin 10 . Such phenomena might be responsible for a defect in a centrosomal function through a dominant negative effect. Nevertheless, we cannot exclude that the mutations associated with CNM might also alter other mechanisms that involve the DNM2 middle domain. Furthermore, immunohistochemical analysis with polyclonal DNM2 antibody on muscle biopsy samples from five affected individuals and four controls showed no differences in labeling intensity, despite some mild changes in labeling distribution, which were probably due to the particular rearrangement of the intermyofibrillar network (data not shown). In addition, the microtubular network visualized by a-tubulin labeling appeared correctly organized in fibroblasts from individuals with CNM (Fig. 1d) . Even if microtubule nucleation is probably not impaired in fibroblasts from individuals with CNM, the situation could differ in skeletal muscle; during differentiation, centrosomes disappear and the microtubuleorganizing center is redistributed near the nuclear membrane and in some new cytoplasmic sites of nucleation 14 . Concurrently, the microtubular network is rearranged longitudinally along the axis of differentiated myotubes. It remains to be determined whether DNM2 has a role in this reorganization in muscle and in the positioning of nuclei 15 .
In summary, our results represent the first report to our knowledge of a gene mutated in dominant CNM. We identified several missense mutations in the middle domain of DNM2 that result in altered centrosomal localization of DNM2 in vitro. Considering the broad range of the cellular mechanisms in which DNM2 is involved, our study opens new avenues for understanding better the pathophysiology of the CNMs.
Note: Supplementary information is available on the Nature Genetics website.
